Part 2: Chronic Lymphocytic Leukemia

Kami J. Maddocks, MD

Assistant professor of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH

Samantha M. Jaglowski, MD

Assistant professor of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH

Question 5

Following treatment, the patient in Question 1 attains a complete response. Following initial chemotherapy, what is the most appropriate approach to treatment?

  •   Maintenance rituximab
  •   Maintenance IV alemtuzumab
  •   Maintenance subcutaneous alemtuzumab
  •   Observation until the patient again meets IWCLL criteria for treatment

Updated 08/17/2012 • jdw | Copyright ©2014 Turner White Communications